AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy
AstraZeneca PLC (AZ, NASDAQ: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS) announced that Wainua (eplontersen) has received approval...
NASDAQ: IONS
Ionis Pharmaceuticals’ DAWNZERA Approved by FDA for HAE Prevention
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced on August 22, 2025, that the U.S. Food and...
AstraZeneca’s Wainzua Earns CHMP Nod for hATTR-PN Treatment in the EU
UK pharmaceutical juggernaut AstraZeneca (AZ, NASDAQ: AZN) has announced that Wainzua (eplontersen), an RNA-targeted therapy...
Biogen Discontinues Aduhelm Development, Redirects Focus to Other Alzheimer’s Therapies
Biogen (NASDAQ: BIIB) has announced its decision to discontinue the development and commercialization of its...
AstraZeneca Secures FDA Approval for Self-Administered hATTR-PN Therapy Wainua
AstraZeneca (AZ, NASDAQ: AZN), headquartered in the UK, announced last week that the U.S. Food...
Biogen’s BIIB080 Shows Promise in Phase Ib Trial for Mild Alzheimer’s Disease
Biogen (NASDAQ: BIIB) has released preliminary findings from a Phase Ib trial for BIIB080, a...
Roche Secures Global Rights to Ionis Pharmaceuticals’ Alzheimer’s and Huntington’s Disease Candidates
Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop,...
Novartis AG and Ionis Pharmaceuticals Renew Collaboration on Lp(a)-Driven CVD Drug
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has returned to US-based Ionis Pharmaceuticals Inc., (NASDAQ:...